Literature DB >> 25336239

HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation.

Z-H Lu1, N Liu, R Bai, Y Yao, S-N Li, R-H Yu, C-H Sang, R-B Tang, D-Y Long, X Du, J-Z Dong, C-S Ma.   

Abstract

AIMS: The aim of this study was to evaluate whether the levels of HbA1c could predict the outcome of ablation in patients with type 2 diabetes mellitus (T2DM) and paroxysmal atrial fibrillation (PAF). PATIENTS AND METHODS: The study comprised 149 consecutive patients with T2DM and PAF who underwent their first circumferential pulmonary vein isolation. HbA1c levels were measured before ablation. Cox proportional hazards models were constructed to assess the relationship between HbA1c levels and the recurrence of atrial fibrillation (AF).
RESULTS: Of the 149 patients, 60 (40.3 %) developed AF recurrence after a median 12-month follow-up. Multivariate Cox regression analysis revealed that left atrium size and HbA1c were independent predictors of recurrent atrial tachyarrhythmia. Receiver operating characteristic analysis demonstrated that an HbA1c cut-off value of ≥ 6.9 % predicted recurrence with 55.0 % sensitivity and 67.4 % specificity (AUC = 0.634). The success rate of ablation was 69.0 % in patients with an HbA1c value of < 6.9 % compared with 46.8 % in those with an HbA1c value of ≥ 6.9 % (log-rank test, p = 0.004).
CONCLUSION: High levels of HbA1c were associated with an increased risk of recurrence of atrial tachyarrhythmia in patients with T2DM and PAF undergoing catheter ablation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25336239     DOI: 10.1007/s00059-014-4154-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  27 in total

1.  What are arrhythmogenic substrates in diabetic rat atria?

Authors:  Takeshi Kato; Takeshi Yamashita; Akiko Sekiguchi; Kouichi Sagara; Masayuki Takamura; Shigeo Takata; Shuichi Kaneko; Tadanori Aizawa; Long-Tai Fu
Journal:  J Cardiovasc Electrophysiol       Date:  2006-06-06

Review 2.  Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation.

Authors:  Rachel R Huxley; Kristian B Filion; Suma Konety; Alvaro Alonso
Journal:  Am J Cardiol       Date:  2011-04-27       Impact factor: 2.778

3.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

4.  Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links.

Authors:  Gregory Y H Lip; George I Varughese
Journal:  Int J Cardiol       Date:  2005-12-07       Impact factor: 4.164

5.  Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits.

Authors:  Changle Liu; Huaying Fu; Jian Li; Wansong Yang; Lijun Cheng; Tong Liu; Guangping Li
Journal:  Anadolu Kardiyol Derg       Date:  2012-08-08

6.  Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Authors:  Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

7.  Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension.

Authors:  Loek van Heerebeek; Nazha Hamdani; M Louis Handoko; Ines Falcao-Pires; René J Musters; Koba Kupreishvili; Alexander J J Ijsselmuiden; Casper G Schalkwijk; Jean G F Bronzwaer; Michaela Diamant; Attila Borbély; Jolanda van der Velden; Ger J M Stienen; Gerrit J Laarman; Hans W M Niessen; Walter J Paulus
Journal:  Circulation       Date:  2007-12-10       Impact factor: 29.690

8.  The influence of insulin resistance and obesity on left atrial size in Japanese hypertensive patients.

Authors:  Yuji Shigematsu; Sadako Norimatsu; Akiyoshi Ogimoto; Tomoaki Ohtsuka; Hideki Okayama; Jitsuo Higaki
Journal:  Hypertens Res       Date:  2009-04-17       Impact factor: 3.872

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy.

Authors:  Giovanni B Forleo; Massimo Mantica; Lucia De Luca; Roberto Leo; Luca Santini; Stefania Panigada; Valerio De Sanctis; Augusto Pappalardo; Francesco Laurenzi; Andrea Avella; Michela Casella; Antonio Dello Russo; Francesco Romeo; Gemma Pelargonio; Claudio Tondo
Journal:  J Cardiovasc Electrophysiol       Date:  2008-09-03
View more
  10 in total

Review 1.  Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?

Authors:  M Matta; A Saglietto; P De Salvo; A Bissolino; A Ballatore; M Anselmino
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

2.  QTc interval predicts outcome of catheter ablation in paroxysmal atrial fibrillation patients with type 2 diabetes mellitus.

Authors:  Ning Ma; Xiao-Yan Wu; Chang-Sheng Ma; Nian Liu; Rong Bai; Xin Du; Yan-Fei Ruan; Jian-Zeng Dong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

3.  Diabetes mellitus contributes to carbamazepine resistance in patient with trigeminal neuralgia.

Authors:  Anke Zhang; Wenbo Zhang; Houshi Xu; Chenqi Guo; Ling Yuan; Yuanzhi Xu; Jie Ren; Lingzhao Min; Qiuyang Sun; Meiqing Lou; Lili Wei; Shaojian Lin
Journal:  Neurosurg Rev       Date:  2020-04-24       Impact factor: 3.042

Review 4.  Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.

Authors:  Shariq I Sherwani; Haseeb A Khan; Aishah Ekhzaimy; Afshan Masood; Meena K Sakharkar
Journal:  Biomark Insights       Date:  2016-07-03

Review 5.  Serum glycated hemoglobin level as a predictor of atrial fibrillation: A systematic review with meta-analysis and meta-regression.

Authors:  Wenwei Qi; Nixiao Zhang; Panagiotis Korantzopoulos; Konstantinos P Letsas; Min Cheng; Fusheng Di; Gary Tse; Tong Liu; Guangping Li
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

6.  Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation.

Authors:  Milton Packer
Journal:  Eur Heart J       Date:  2019-06-14       Impact factor: 29.983

7.  Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue.

Authors:  Milton Packer
Journal:  Cardiovasc Diabetol       Date:  2019-09-24       Impact factor: 9.951

Review 8.  Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Dimitrios V Moysidis; Christos Tsagkaris; Stavros P Papadakos; Alexandra Bekiaridou; Athanasios Samaras; Efstratios Karagiannidis; Marios Papadakis; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2022-03-14       Impact factor: 9.951

9.  Risk Factors for Failure of Direct Current Cardioversion in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.

Authors:  Handrean Soran; Moulinath Banerjee; Jamal B Mohamad; Safwaan Adam; Jan Hoong Ho; Shakawan M Ismaeel; Shaishav Dhage; Akheel A Syed; Ibrahem M A Abdulla; Naveed Younis; Rayaz A Malik
Journal:  Biomed Res Int       Date:  2018-03-12       Impact factor: 3.411

Review 10.  Characterization, Pathogenesis, and Clinical Implications of Inflammation-Related Atrial Myopathy as an Important Cause of Atrial Fibrillation.

Authors:  Milton Packer
Journal:  J Am Heart Assoc       Date:  2020-04-03       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.